{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:32:44Z","timestamp":1771003964593,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,2,8]],"date-time":"2013-02-08T00:00:00Z","timestamp":1360281600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s10198-013-0456-5","type":"journal-article","created":{"date-parts":[[2013,2,7]],"date-time":"2013-02-07T09:30:42Z","timestamp":1360229442000},"page":"69-82","source":"Crossref","is-referenced-by-count":19,"title":["Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom"],"prefix":"10.1007","volume":"15","author":[{"given":"Yevgeniy","family":"Samyshkin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Kotchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Christin","family":"M\u00f6rk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew H.","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric D.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,2,8]]},"reference":[{"issue":"3","key":"456_CR1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1183\/09031936.06.00124605","volume":"28","author":"RJ Halbert","year":"2006","unstructured":"Halbert, R.J., Natoli, J.L., Gano, A., Badamgarav, E., Buist, A.S., Mannino, D.M.: Global burden of COPD: systematic review and meta-analysis. Eur. Respir. J. 28(3), 523\u2013532 (2006)","journal-title":"Eur. Respir. J."},{"key":"456_CR2","unstructured":"Global Strategy for the Diagnosis, Management, and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2011)"},{"issue":"3","key":"456_CR3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/15412550701480265","volume":"4","author":"PW Jones","year":"2007","unstructured":"Jones, P.W.: Activity limitation and quality of life in COPD. COPD 4(3), 273\u2013278 (2007)","journal-title":"COPD"},{"issue":"112","key":"456_CR4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1183\/09059180.00001309","volume":"18","author":"N Roche","year":"2009","unstructured":"Roche, N.: Activity limitation: a major consequence of dyspnoea in COPD. Eur. Respir.Rev. 18(112), 54\u201357 (2009)","journal-title":"Eur. Respir.Rev."},{"key":"456_CR5","unstructured":"Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. National Institute for Health and Clinical Excellence (2010)"},{"issue":"9691","key":"456_CR6","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","volume":"374","author":"PM Calverley","year":"2009","unstructured":"Calverley, P.M., Rabe, K.F., Goehring, U.M., Kristiansen, S., Fabbri, L.M., Martinez, F.J.: Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374(9691), 685\u2013694 (2009)","journal-title":"Lancet"},{"issue":"3","key":"456_CR7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1155\/2007\/921914","volume":"14","author":"JM FitzGerald","year":"2007","unstructured":"FitzGerald, J.M., Haddon, J.M., Bradly-Kennedy, C., Kuramoto, L., Ford, G.T.: Resource use study in COPD (RUSIC): a prospective study to quantify the effects of COPD exacerbations on health care resource use among COPD patients. Can Respir J. 14(3), 145\u2013152 (2007)","journal-title":"Can Respir J."},{"issue":"9","key":"456_CR8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.rmed.2004.02.013","volume":"98","author":"JB Oostenbrink","year":"2004","unstructured":"Oostenbrink, J.B., Rutten-van M\u00f6lken, M.P.: Resource use and risk factors in high-cost exacerbations of COPD. Respir. Med. 98(9), 883\u2013891 (2004)","journal-title":"Respir. Med."},{"issue":"10","key":"456_CR9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/thorax.57.10.847","volume":"57","author":"GC Donaldson","year":"2002","unstructured":"Donaldson, G.C., Seemungal, T.A., Bhowmik, A., Wedzicha, J.A.: Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57(10), 847\u2013852 (2002)","journal-title":"Thorax"},{"issue":"10","key":"456_CR10","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/thx.2008.110619","volume":"64","author":"S Guerra","year":"2009","unstructured":"Guerra, S., Sherrill, D.L., Venker, C., Ceccato, C.M., Halonen, M., Martinez, F.D.: Chronic bronchitis before age 50\u00a0years predicts incident airflow limitation and mortality risk. Thorax 64(10), 894\u2013900 (2009)","journal-title":"Thorax"},{"issue":"6","key":"456_CR11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/thx.2009.126052","volume":"65","author":"S Guerra","year":"2010","unstructured":"Guerra, S., Sherrill, D.L., Venker, C., Ceccato, C.M., Halonen, M., Martinez, F.D.: Morbidity and mortality associated with the restrictive spirometric pattern: a longitudinal study. Thorax 65(6), 499\u2013504 (2010)","journal-title":"Thorax"},{"issue":"1","key":"456_CR12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1524-4733.2005.03086.x","volume":"8","author":"JB Oostenbrink","year":"2005","unstructured":"Oostenbrink, J.B., Rutten-van M\u00f6lken, M.P., Monz, B.U., FitzGerald, J.M.: Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 8(1), 32\u201346 (2005)","journal-title":"Value Health"},{"issue":"7","key":"456_CR13","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1513\/pats.200603-095SS","volume":"3","author":"MP Rutten-van M\u00f6lken","year":"2006","unstructured":"Rutten-van M\u00f6lken, M.P., Lee, T.A.: Economic modeling in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 3(7), 630\u2013634 (2006)","journal-title":"Proc. Am. Thorac. Soc."},{"key":"456_CR14","unstructured":"European Public Assessment Report (EPAR) for Daxas. Product information. 28\/03\/2011 Daxas -EMEA\/H\/C\/001179-IB\/0002. 20-7-2010 (2010)"},{"issue":"3","key":"456_CR15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1183\/09031936.00178710","volume":"38","author":"ED Bateman","year":"2011","unstructured":"Bateman, E.D., Rabe, K.F., Calverley, P.M., Goehring, U.M., Brose, M., Bredenbr\u00f6ker, D., Fabbri, L.M.: Roflumilast with long-acting \u00df2 agonists for COPD: influence of exacerbation history. Eur. Respir. J. 38(3), 553\u2013560 (2011)","journal-title":"Eur. Respir. J."},{"key":"456_CR16","unstructured":"Selected subgroup analyses based on data from Studies M2-124 and M2-125 in subpopulation of LABA-treated patients and subpopulation of LABA-treated patients with at least two COPD exacerbations in the previous year. 16-7-2010. Nycomed International Management GmbH (2010)"},{"issue":"6","key":"456_CR17","first-page":"659","volume":"123","author":"RO Crapo","year":"1981","unstructured":"Crapo, R.O., Morris, A.H., Gardner, R.M.: Reference spirometric values using techniques and equipment that meet ATS recommendations. Am. Rev. Respir. Dis. 123(6), 659\u2013664 (1981)","journal-title":"Am. Rev. Respir. Dis."},{"key":"456_CR18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/ajrccm.161.2.9901044","volume":"161","author":"PD Scanlon","year":"2000","unstructured":"Scanlon, P.D., Connett, J.E., Waller, L.A., Altose, M.D., Bailey, W.C., Buist, A.S.: Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am. J. Respir. Crit. Care Med. 161, 381\u2013390 (2000)","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"456_CR19","unstructured":"Statistical report. Effect of roflumilast on exacerbation rates in based on data from studies M2-124 and M2-125 in subpopulation of LABA-treated patients. Nycomed International Management GmbH (2009)"},{"key":"456_CR20","unstructured":"Report of the 2008 National COPD Audit: The Royal College of Physicians and the British Thoracic Society (2008)"},{"issue":"3","key":"456_CR21","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1183\/09031936.00043710","volume":"37","author":"M Hoogendoorn","year":"2011","unstructured":"Hoogendoorn, M., Hoogenveen, R.T., Rutten-van M\u00f6lken, M.P., Vestbo, J., Feenstra, T.L.: Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur. Respir. J. 37(3), 508\u2013515 (2011)","journal-title":"Eur. Respir. J."},{"issue":"1","key":"456_CR22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1465-9921-6-98","volume":"6","author":"M Ekberg-Aronsson","year":"2005","unstructured":"Ekberg-Aronsson, M., Pehrsson, K., Nilsson, J.A., Nilsson, P.M., Lofdahl, C.G.: Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir. Res. 6(1), 98 (2005). doi: 10.1186\/1465-9921-6-98","journal-title":"Respir. Res."},{"issue":"6","key":"456_CR23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/00019053-200927060-00003","volume":"27","author":"MP Rutten-van M\u00f6lken","year":"2009","unstructured":"Rutten-van M\u00f6lken, M.P., Hoogendoorn, M., Lamers, L.M.: Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. Pharmacoeconomics 27(6), 465\u2013477 (2009)","journal-title":"Pharmacoeconomics"},{"key":"456_CR24","unstructured":"British National Formulary. British Medical Association and Royal Pharmaceutical Society, London (2010)"},{"key":"456_CR25","unstructured":"NHS reference costs 2009\u20132010. 13-1-2011. UK Department of Health (2011)"},{"issue":"4","key":"456_CR26","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/hec.985","volume":"14","author":"K Claxton","year":"2005","unstructured":"Claxton, K., Sculpher, M., McCabe, C., Briggs, A., Akehurst, R., Buxton, M., Brazier, J., O\u2019Hagan, T.: Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 14(4), 339\u2013347 (2005)","journal-title":"Health Econ."},{"issue":"2","key":"456_CR27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1524-4733.2004.72318.x","volume":"7","author":"S Borg","year":"2004","unstructured":"Borg, S., Ericsson, A., Wedzicha, J., Gulsvik, A., Lundb\u00e4ck, B., Donaldson, G.C., Sullivan, S.D.: A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 7(2), 153\u2013167 (2004)","journal-title":"Value Health"},{"issue":"1","key":"456_CR28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.rmed.2008.10.005","volume":"103","author":"SR Earnshaw","year":"2009","unstructured":"Earnshaw, S.R., Wilson, M.R., Dalal, A.A., Chambers, M.G., Jhingran, P., Stanford, R., Mapel, D.W.: Cost-effectiveness of fluticasone propionate\/salmeterol (500\/50 microg) in the treatment of COPD. Respir. Med. 103(1), 12\u201321 (2009)","journal-title":"Respir. Med."},{"issue":"4","key":"456_CR29","first-page":"226","volume":"15","author":"Y Oba","year":"2009","unstructured":"Oba, Y.: Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. Am. J. Manag. Care 15(4), 226\u2013232 (2009)","journal-title":"Am. J. Manag. Care"},{"issue":"6","key":"456_CR30","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2165\/00019053-200523060-00008","volume":"23","author":"M Spencer","year":"2005","unstructured":"Spencer, M., Briggs, A.H., Grossman, R.F., Rance, L.: Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 23(6), 619\u2013637 (2005)","journal-title":"Pharmacoeconomics"},{"key":"456_CR31","unstructured":"Calverley, P.M., Anderson, J.A., Celli, B., Ferguson, G.T., Jenkins, C., Jones, P.W., Yates, J.C., Vestbo, J., TORCH investigators.: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356(8), 775\u2013789 (2007)"},{"issue":"3","key":"456_CR32","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.pupt.2007.12.004","volume":"21","author":"NA Hanania","year":"2008","unstructured":"Hanania, N.A.: The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD. Pulm. Pharmacol. Ther. 21(3), 540\u2013550 (2008)","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"10","key":"456_CR33","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.rmed.2010.03.033","volume":"104","author":"D Tashkin","year":"2010","unstructured":"Tashkin, D., Celli, B., Kesten, S., Lystig, T., Decramer, M.: Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. Respir. Med. 104(10), 1495\u20131504 (2010)","journal-title":"Respir. Med."},{"key":"456_CR34","doi-asserted-by":"crossref","unstructured":"Tashkin, D.P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., Decramer, M., UPLIFT Study Investigators.: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 359(15), 1543\u20131554 (2008)","DOI":"10.1056\/NEJMoa0805800"},{"key":"456_CR35","doi-asserted-by":"crossref","unstructured":"Martinez, F.J., Rabe, K.F., Goehring, U.M., Lakkis, H., Rowe, P., Palm, U.: Roflumilast prolongs time to first and subsequent exacerbations in patients with severe to very severe COPD. In: American Thoracic Society International Conference. ATS-2011. Denver, Colorado, USA. 13-5-2011 (2011)","DOI":"10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A5373"},{"key":"456_CR36","doi-asserted-by":"crossref","unstructured":"Mills, E.J., Druyts. E., Ghement, I., Puhan M.A.: Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clin. Epidemiol. 3, 107\u2013129 (2011)","DOI":"10.2147\/CLEP.S16235"},{"key":"456_CR37","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2147\/COPD.S29820","volume":"7","author":"N Hertel","year":"2012","unstructured":"Hertel, N., Kotchie, R.W., Samyshkin, Y., Radford, M., Humphreys, S., Jameson, K.: Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 7, 183\u2013199 (2012)","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"1","key":"456_CR38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1476-5381.2011.01218.x","volume":"163","author":"KF Rabe","year":"2011","unstructured":"Rabe, K.F.: Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br. J. Pharmacol. 163(1), 53\u201367 (2011)","journal-title":"Br. J. Pharmacol."},{"key":"456_CR39","unstructured":"Personal Social Services Research Unit, UK. Unit Costs of Health and Social Care 2009. http:\/\/www.pssru.ac.uk\/archive\/pdf\/uc\/uc2009\/uc2009.pdf (2009)"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-013-0456-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10198-013-0456-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-013-0456-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T11:15:28Z","timestamp":1562670928000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10198-013-0456-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,8]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["456"],"URL":"https:\/\/doi.org\/10.1007\/s10198-013-0456-5","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,8]]}}}